Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

TAKTakedaRunning, no new patients

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Hodgkin Disease

5Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 2 insiders sold shares within a month

    Since Nov 4, 2026 · was worth 5, fading over time

    +4.9
Worry score5

Score over time

Stage
Phase 1/2
Patients
59 (final count)
Started
Sep 6, 2017
Main results expected
May 5, 2020
Fully finished
Sep 24, 2029
Results posted
Jun 1, 2021

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population

    Measured over: From the first dose (Cycle 1) up to Day 56 (Cycle length=28 days)

  • Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

    Measured over: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)

  • Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

    Measured over: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)

  • Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit

    Measured over: At end of treatment (EOT) visit 30 days after the last dose of study drug (at Month 7)

  • Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment

    Measured over: From first dose of study drug up to Cycle 2 Day 25 (Each Cycle length=28 days)

  • Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit

    Measured over: At EOT visit 30 days after the last dose of study drug (at Month 7)

  • Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit

    Measured over: At EOT visit 30 days after the last dose of study drug (at Month 7)

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT02979522 · record last updated 2025-11-10 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT02979522) ↗

Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose

Measured over: From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)